Kronos Bio, Inc.
News
After Plunging -5.53% in 4 Weeks, Here's Why the Trend Might Reverse for Kronos Bio (KRON)
Zacks Investment Research A downtrend has been apparent in Kronos Bio, Inc. (KRON) lately with too much selling pressure. The stock has declined 5.5% over the past four weeks. However, given the fact that it is now in...\n more…
Kronos Bio Announces Participation in Medical and Investor Conferences in September
Globe Newswire SAN MATEO, Calif., and CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and...\n more…
After Plunging -23.49% in 4 Weeks, Here's Why the Trend Might Reverse for Kronos Bio (KRON)
Zacks Investment Research Kronos Bio, Inc. (KRON) has been on a downward spiral lately with significant selling pressure. After declining 23.5% over the past four weeks, the stock looks well positioned for a trend reversal as...\n more…
HC Wainwright Weighs in on Kronos Bio, Inc.'s Q3 2024 Earnings (NASDAQ:KRON)
Ticker Report Kronos Bio, Inc. (NASDAQ:KRON - Free Report) - HC Wainwright increased their Q3 2024 earnings estimates for Kronos Bio in a report issued on Monday, August 19th. HC Wainwright analyst R. Burns now...\n more…
Kronos Bio (NASDAQ:KRON) Stock Rating Reaffirmed by HC Wainwright
Ticker Report HC Wainwright reiterated their buy rating on shares of Kronos Bio (NASDAQ:KRON - Free Report) in a report released on Monday morning, Benzinga reports. They currently have a $2.25 target price on the...\n more…